Tenecteplase

Indications

• • Myocardial infarction

  • thrombolytic

Administration/Absorption

Dosage

Distribution

Mechanism

• • tissue plasminogen activator (tPA)

    • produced by recombinant DNA technology using an established mammalian cell line

  • derived from native t-PA by modifications at three sites of the protein structure

  • higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA.

Excretion

Side effects

Interactions

Contraindications